## Introduction to Other Drug-Induced Agranulocytosis Drug-induced agranulocytosis (DIA) is a severe, life-threatening hematologic condition characterized by a profound reduction in the peripheral absolute neutrophil count (ANC), typically falling below 500 cells/µL. Within the ICD-10 framework, D70.2 refers to 'Other drug-induced agranulocytosis.' This classification is critical for identifying cases where medications, other than specific antineoplastics or those otherwise categorized, trigger a sudden and severe depletion of neutrophils. Because neutrophils are the body's primary defense against bacterial and fungal pathogens, their absence predisposes patients to rapid-onset sepsis and multi-organ failure. ## Pathophysiology and Mechanisms The pathophysiology of drug-induced agranulocytosis generally involves two distinct pathways: immune-mediated destruction and direct myelotoxicity. In immune-mediated DIA, the offending drug or its metabolite acts as a hapten, binding to the surface of neutrophils or myeloid precursors and stimulating the production of drug-dependent antibodies (usually IgG or IgM). This leads to the rapid peripheral destruction of cells. Conversely, direct myelotoxicity involves the drug interfering with the metabolic processes or DNA synthesis within the bone marrow's myeloid lineage, leading to a maturation arrest of granulocyte precursors. Unlike the idiosyncratic nature of immune-mediated reactions, myelotoxic reactions may sometimes exhibit dose-dependent characteristics, though they remain distinct from the predictable marrow suppression seen with cytotoxic chemotherapy. ## Clinical Presentation and Diagnostic Criteria Patients with DIA often present acutely with symptoms of 'agranulocytic angina,' which includes high fever, severe sore throat, and painful necrotic ulcers in the mouth and pharynx. Because the inflammatory response is compromised, typical signs of infection (like pus formation) may be absent, making clinical detection challenging. Diagnosis requires a Complete Blood Count (CBC) with differential confirming an ANC < 500/µL. A detailed medication history is paramount, focusing on drugs introduced within the preceding 3 to 6 months. Bone marrow aspiration and biopsy are frequently performed to exclude other causes of pancytopenia, such as leukemia or aplastic anemia, often revealing a myeloid-specific hypoplasia or maturation arrest at the promyelocyte stage. ## Management and Standard of Care The immediate and absolute withdrawal of the suspected causative agent is the most critical therapeutic intervention. Management is largely supportive, involving hospitalization in a private room and the initiation of broad-spectrum empirical intravenous antibiotics (e.g., carbapenems or piperacillin-tazobactam) at the first sign of fever. The use of Granulocyte Colony-Stimulating Factor (G-CSF) is common clinical practice to shorten the duration of neutropenia, potentially reducing the risk of fatal infectious complications. Once the ANC recovers above 1,500/µL, the patient is generally considered out of the acute danger zone, but the offending drug must be permanently added to the patient's allergy list to prevent recurrence.
Distinguish between adverse effect and poisoning for the causal drug.
Example: Patient presenting with fever and severe sore throat while on Methimazole for Grave's disease. Lab work confirms ANC of 250/µL. Condition identified as an adverse effect of correctly prescribed and administered medication (T38.2X5A). Risk adjustment: Patient is at high risk for sepsis and requires immediate hospitalization for neutropenic precautions.
Billing Focus: Use T-code sequence for adverse effect (T36-T50) with 5th or 6th character '5'.
Document the specific Absolute Neutrophil Count (ANC) to support severity.
Example: 65-year-old female on Clozapine for refractory schizophrenia. Routine monitoring shows ANC of 400/µL, meeting criteria for D70.2. Assessment: Chronic drug-induced agranulocytosis. Management: Immediate cessation of Clozapine and initiation of Filgrastim. Risk adjustment: Severe chronic condition with life-threatening complications.
Billing Focus: Specificity of 'agranulocytosis' over 'neutropenia' is required when ANC is <500/µL.
Link secondary infections and their causal relationship to agranulocytosis.
Example: Agranulocytosis due to Sulfasalazine use (D70.2). Patient has developed secondary Pseudomonas aeruginosa pneumonia (J15.1). Note reflects that the pneumonia is a direct consequence of the drug-induced immunosuppression. Plan: IV Piperacillin-Tazobactam and isolation.
Billing Focus: Sequence D70.2 as the primary diagnosis followed by the manifestation/infection code.
Document the 'episode of care' (Initial, Subsequent, Sequela) for the causal agent T-code.
Example: Subsequent encounter for drug-induced agranulocytosis following initial stabilization. Patient is now being transitioned from inpatient to outpatient monitoring of ANC. Coding: D70.2, T43.3X5D (Adverse effect of antipsychotics, subsequent).
Billing Focus: 7th character 'D' for subsequent encounters is vital for claim accuracy in drug-related injury.
Specify the drug class or agent explicitly in the narrative.
Example: Diagnosis: Other drug-induced agranulocytosis (D70.2) secondary to chronic Carbamazepine therapy for trigeminal neuralgia. ANC 350. Billing focus: Identifying 'Other' implies a non-chemotherapeutic agent. Risk adjustment: Chronic management of hematological toxicities impacts the complex care management score.
Billing Focus: Explicitly naming the drug class helps coders select the most specific T-code companion.
Essential for diagnosing and monitoring the severity of agranulocytosis (ANC < 500).
Standard for managing a patient with drug-induced agranulocytosis requiring drug discontinuation and new treatment planning.
Used for patients with agranulocytosis and active infection or systemic symptoms requiring complex decision making.
Used to rule out other causes of marrow failure like myelodysplastic syndrome or leukemia.
Commonly used for the administration of G-CSF (Filgrastim) to stimulate neutrophil production.
Frequent monitoring of WBC is required to track recovery from D70.2.
Initial consultation for a patient referred from primary care due to drug-related marrow suppression.
Follow-up visit once the drug has been discontinued and ANC is recovering toward normal.
Occasionally used if the underlying cause of the fever in an agranulocytic patient is infectious.
Hospitalization is common for D70.2 when ANC is severely low and infection is suspected.